6. Subjective health status.

Study	Condition	No. of participants	Timing of outcome measurement	Generic health status	Other generic measures not included in meta‐analysis	Condition‐specific health status	Results as reported
Battersby 2007	Various	1703 (124 included in meta‐analysis)	12 months	SF‐36 (PCS, MCS)	WSAS		No significant effects
Glasgow 2005a	Diabetes	886	12 months			PAID‐2	No significant effects
Katon 2010a	Depression + diabetes/CHD	214	12 months		WHODAS‐2, Sheehan disability scale, global rating score		Sheehan improved Global rating improved
Kennedy 2013	Diabetes, COPD, IBS	5599	12 months		Selected subscales of SF‐36, EQ‐5D		No significant effects
Liu 2012	Diabetes	208	12 months			Stanford Illness Intrusiveness	Illness intrusiveness improved
Schillinger 2009	Diabetes	226	12 months	SF‐12 (PCS, MCS)			No significant effects
Shearer 2007	Heart failure	90	3 months	SF‐36 (PCS, MCS)			No significant effects
Wilson 2010	Asthma	408	12 months			AQLQ	AQLQ improved
Wolever 2010	Diabetes	56	6 months		SF‐12 (single score)		No significant effects
Zoffmann 2006	Diabetes	61	12 months			PAID‐2	No significant effects

AQLQ: Asthma Quality of Life Questionnaire; CHD: coronary heart disease; COPD: chronic obstructive pulmonary disease; EQ‐5D: Euro‐Qol; IBS: irritable bowel syndrome; PAID‐2: Problem Areas in Diabetes scale; SF‐36, SF‐12 (PCS, MCS): Health survey (physical component score, mental component score);
 WHODAS: WHO Disability Assessment Schedule; WSAS: Work and Social Adjustment Scale